Tumor therapy with bispecific antibody: The targeting and triggering steps can be separated employing a CD2-based strategy

Journal of Immunology

Volumn 163, Issue 4, 1999, Pages 2064-2072

  Wild, Martin K ^a   Strittmatter, Wolfgang ^b   Matzku, Siegfried ^b   Schraven, Burkhart ^a   Meuer, Stefan C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MERCK KGAA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD2 ANTIGEN; CD3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN F(AB')2 FRAGMENT; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR;

ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD2; ANTINEOPLASTIC AGENTS; BINDING SITES; CELLS, CULTURED; CLONE CELLS; COCULTURE TECHNIQUES; CYTOTOXICITY TESTS, IMMUNOLOGIC; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOCONJUGATES; IMMUNOGLOBULIN FAB FRAGMENTS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; RECEPTOR, EPIDERMAL GROWTH FACTOR; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0033567015     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. van de Winkel, J. G. J., B. Bast, and G. C. de Gast. 1997. Immunotherapeutic potential of bispecific antibodies. Immunol. Today 18:562.
2. Barclay, A. N., M. H. Brown, S. K. A. Law, McKnight, A. J., Tomlinson, M. G, and P. A. van der Merwe. 1997. The Leukocyte Antigen Facts Book. 2nd Ed. Academic Press, San Diego.
3. Meuer, S. C., R. E. Hussey, M. Fabbi, D. Fox, O. Acuto, K. A. Fitzgerald, J. C. Hodgdon, J. P. Protentis, S. F. Schlossman, and E. L. Reinherz. 1984. An alternative pathway of T cell activation: a functional role for the 50 kDa T11 sheep erythrocyte receptor protein. Cell 36:897.
4. Siliciano, R. F., J. C. Pratt, R. E. Schmidt, J. Ritz, and E. L. Reinherz. 1985. Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature 317:428.
5. Schraven, B., M. Roux, B. Hutmacher, and S.C. Meuer. 1989. Triggering of the alternative pathway of human T cell activation involves members of the T200 family of glycoproteins. Eur. J. Immunol. 19:397.
6. Samstag, Y., A. Bader, and S. C. Meuer. 1991. A serine phosphatase is involved in CD2-mediated activation of human T lymphocytes and natural killer cells. J. Immunol. 147:788.
7. Schneider, U., H. U. Schwenk, and G. Bornkamm. 1977. Characterization of EBV-genome negative "null" and T cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int. J. Cancer 19:621.
8. Haigler, H., J. F. Ash, S. J. Singer, and S. Cohen. 1978. Visualization of fluorescence of binding and internalization of epidermal growth factor in human carcinoma cells A431. Proc. Natl. Acad. Sci. USA 75:3317.
9. Lozzio, C. B., and B. B. Lozzio. 1975. Human chronic myelogenous leukemia cell-line with posilive Philadelphia chromosome. Blood 45:321.
10. Welch, D. R., J. E. Bisi, B. E. Miller, D. Conaway, E. A. Seftor, K. H. Yohem, L. B. Gilmore, R. E. Seftor, M. Nakajima. and M. J. Hendrix. 1991. Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int. J. Cancer 47:227.
11. Deusch, K., U. Moebius, K.-H. Meyer zum Büschenfelde, and S. C. Meuer. 1986. T lymphocyte control of autoreactivity: analysis with human T-cell clones and limiting dilution culture. Eur. J. Immunol. 16:1433.
12. Shimizu, Y., E. Weidmann, S. Iwatsuki, R. B. Herberman, and T. L. Whiteside. 1991. Characterization of human autotumor-reactive T-cell clones obtained from tumor-infiltrating lymphocytes in liver metastasis of gastric carcinoma. Cancer Res. 51:6153.
13. Knuth, A., T. Wölfel, E. Klehmann, T. Boon, and K.-H. Meyer zum Buschenfelde. 1989. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc. Natl. Acad. Sci. USA 86:2804.
14. Dengler, T. J., J. C. Hoffmann, P. Knolle, M. Albert-Wolf, M. Roux, R. Wallich, and S. C. Meuer. 1992. Structural and functional epitopes of the human adhesion receptor CD58 (LFA-3). Eur. J. Immunol. 22:2809.
15. Rodeck, U., M. Herlyn, C. Molthoff, and et.al. 1987. Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects. Cancer Res. 47:3692.
16. Brennan, M., P. F. Davidson, and H. Paulus. 1985. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229:81.
17. Albert-Wolf, M., S. C. Meuer, and R. Wallich. 1991. Dual function of recombinant human CD58: inhibition of T cell adhesion and activation via the CD2 pathway. Int. Immunol. 3:1335.
18. Endler-Jobst, B., B. Schraven, B. Hutmacher, and S. C. Meuer. 1991. Human T cell responses to IL-1 and IL-6 are dependent on signals mediated through CD2. J. Immunol. 146:1736.
19. Hünig, T. 1985. The cell surface molecule recognized by the erythrocyte receptor of T lymphocytes. J. Exp. Med. 162:890.
20. Plunkett, M. L., M. E. Sanders, P. Selvaraj, M. L. Dustin, and T. A. Springer. 1987. Rosetting of human T lymphocytes with autologous erythrocytes. J. Exp. Med. 165:664.
21. Van Wauwe, J., J. Goosens, W. Decock, P. Kung, and G. Goldstein. 1981. Suppression of human T-cell mitogenesis and E-rosette formation by the monoclonal antibody OKT11A. Immunology 44:865.
22. Valentin, H., S. Huet, J. Morizet, and A. Bernard. 1989. The delivery of distinct activation signals to T-cells via CD2. In Leukocyte Typing IV. W. Knapp, ed. Oxford University Press, Oxford, p. 272.
23. Wild, M. K., A. M. Verhagen, S. C. Meuer, and B. Schraven. 1997. The receptor function of CD2 in human CD2 transgenic mice is based on highly conserved associations with signal transduction molecules. Cell. Immunol. 180:168.
24. Tiefenthaler, G., T. Hünig, M.L. Dustin, T. A. Springer, and S. C. Meuer. 1987. Purified lymphocyte function-associated antigen-3 and T11 target structure are active in CD2-mediated T cell stimulation. Eur. J. Immunol. 17:1847.
25. 3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells, J. Immunol. 147:60.
26. Lindauer, M., W. Rudy, B. Gückel, M. v. Knebel-Doeberitz, S. C. Meuer, and U. Moebius. 1998. Gene transfer of costimulatory molecules into a human colorectal cancer cell line: requirement of CD54, CD80 and class II MHC expression for enhanced immunogenicity. Immunology 93:390.
27. Segal, D. M., J. H. Qian, D. Mezzanzanica, N. A. Garrido, J. A. Titus, S. M. Andrew, A. J. T. George, C. R. Jost, P. Perez, and J. R. Wunderlich. 1992. Targeting of anti-tumor responses with bispecific antibodies. Immunobiology 185:390.
28. Jacobs, N., A. Mazzoni, D. Mezzanzanica, D. R. Negri, O. Valota, M. I. Colnaghi, M. Moutschen, J. Boniver, and S. Canevari. 1997. Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation. Cancer Immunol. Immunother. 44:257.
29. Bonnefoy-Berard, N., and J. P. Revillard. 1996. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J. Heart Lung Transplant. 15:435.
30. Carpenter, G., and S. Cohen. 1979. Epidermal growth factor. Annu. Rev. Biochen. 48:193.
31. Fanger, M. W., P. M. Morganelli, and P. M. Guyre. 1992. Bispecific antibodies. Crit. Rev. Immunol. 12:101.
32. Lin, J., R. W. Yon, K. D. Chavin, L. Qin, J. Woodward, Y. Ding, H. Yagita, and J. S. Bromberg. 1995. Anti-CD2 monoclonal antibody-induced receptor changes: down modulation of cell surface CD2. Transplantation 59:1162.
33. Meuer, S. C., R. E. Hussey, D. A. Cantrell, J. C. Hodgdon, S. F. Schlossman, K. A. Smith, and E. L. Reinherz. 1984. Triggering of the T3-Ti antigen receptor complex results in clonal T cell proliferation via an interleukin 2 dependent autocrine pathway. Proc. Natl. Acad. Sci. USA 81:1509.
34. Gückel, B., C. Berek, M. Lutz, P. Altevogt, V. Schirrmacher, and B. A. Kyewski. 1991. Anti-CD2 antibodies induce T cell unresponsiveness in vivo. J. Exp. Med. 174:957.
35. Weiner, G. J., S. A. Kostelny, J. R. Hillstrom, M. S. Cole, B. K. Link, S. L. Wang, and J. Yun Tso. 1994. The role of T cell activation in anti-CD3 × antitumor bispecific antibody therapy. J. Immunol. 152:2385.
36. Scott, C. F., J. M. Lambert, R. S. Kalish, C. Morimoto, and S. F. Schlossman. 1988. Human T cells can be directed to lyse tumor targets through the alternative activation/T11-E rosette receptor pathway. J. Immunol. 140:8.
37. Scott, C. F., W. A. Blättler, J. M. Lambert, R. S. Kalish, C. Morimoto, and S. F. Schlossman. 1988. Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells. J. Clin. Invest. 81:1427.
38. Scott, C. F., S. Bolender, G. D. McIntyre, J. Holldack, J. M. Lambert, Y. P. Venkatesh, C. Morimoto, J. Ritz, and S. F. Schlossman. 1989. Activation of human cytolytic cells through CD2/T11: Comparison of the requirements for induction and direction of lysis of tumor targets by T cells and NK cells. J. Immunol. 142:4105.
39. Meuer, S.C., M. Hauer, K. Deusch, U. Moebius, and K.-H. Meyer zum Büschenfelde. 1987. Two pathways of T cell activation. Behring Inst. Mitt. 81:15.
40. Roosnek, E., and A. Lanzavecchia. 1989. Triggering T cells by otherwise inert hybrid anti-CD3/antitumor antibodies requires encounter with the specific target cell. J. Exp. Med. 170:297.
41. Urban, J.L., M. L. Kripke, and H. Schreiber. 1986. Stepwise immunological selection of antigenic variants during tumor growth. J. Immunol. 137:3036.
42. Schreiber, H. 1989. Tumor immunology. In Fundamental Immunology, 2nd Ed. W. E. Paul, ed. Raven Press, New York, p, 923.
43. Bretscher, P., and M. Cohn. 1970. A theory of self-nonself discrimination. Science 169:1042.
44. Guinan, E. C., J. G. Gribben, V. A. Boussiotis, G. J. Freeman, and L. M. Nadler. 1994. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261.
45. Meuer, S. C., B. Schraven, and Y. Samstag. 1994. An "alternative" pathway of T cell activation. Int. Arch. Allergy Immunol. 104:216.
46. 2 and Fab fragments in nude mice with human tumour xenografts: implications for tumor imaging and radioimmunotherapy. Nucl. Med. Commun. 10:585.
47. Molthoff, C. F., J. J. Calame, H. M. Pinedo, and E. Boven. 1991. Human ovarian cancer xenografts in nude mice: characterization and analysis of antigen expression. Int. J. Cancer 47:72.
48. Riethmüller, G., E. Schneider-Gädicke, G. Schlimok, W. Schmiegel, R. Raab, K. Höffken, and R. Gruber. 1994. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet. 343:1177.
49. Whiteside, T. L., and G. Parmiani. 1994. Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use. Cancer Immunol. Immunother. 39:15.
50. Lang, G., D. Wotton, M. J. Owen, W. A. Sewell, M. H. Brown, D. Y. Mason, M. J. Crumpton, and D. Kioussis. 1988. The structure of the human CD2 gene and its expression in transgenic mice. EMBO J. 7:1675.